EGFR and non-small cell lung carcinoma: ) Mutation Testing for Patients With Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy, J Clin Oncol 29:2121-2127, 2011.